why choose us

First received: January 31, 2023

Clinical Trial: HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Relapsed or Refractory Lymphoma

Study Type: Interventional


Official Title: A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, and the Effect of Rifampin on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Brief Summary: A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Read more